Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.50 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.42 |
| ▸ | PDE1A | P54750 | 4/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231771 | 0.92 | PDE7A (0.49) | PDE7A | |
| SCHEMBL5228271 | 0.89 | PDE5A (0.55) | PDE5APDE7APDE1APDE1BPDE1C | |
| SCHEMBL5232305 | 0.87 | PDE7A (0.47) | PDE5APDE7A | |
| SCHEMBL5231988 | 0.85 | PDE7A (0.44) | PDE5APDE7A | |
| SCHEMBL5230862 | 0.84 | PDE7A (0.60) | PDE5APDE7APDE1APDE1BPDE1C | |
| SCHEMBL5229893 | 0.84 | KHK (0.47) | PDE5A | |
| SCHEMBL5229944 | 0.84 | PDE7A (0.46) | PDE5APDE7A | |
| SCHEMBL14395352 | 0.84 | PDE7A (0.47) | PDE5APDE7AHDAC1HDAC6PDE1A | |
| SCHEMBL5234152 | 0.82 | PDE7A (0.49) | PDE7A | |
| SCHEMBL5239214 | 0.82 | PDE7A (0.56) | PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1454897-B1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY | ASUBIO PHARMA CO LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | OMEROS CORPORATION | 2005-07-07 | — | — | US | disclosed |
| EP-1454897-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | PDE7B, PDE3B, PDE3A | PDE5A 8/4885PDE7A 4/4885HDAC1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.